Giant Biogene's (HKG:2367) attributable profit rose 42% to 2.06 billion yuan in 2024 from 1.45 billion yuan in 2023, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share at the skincare products maker increased 39% to 2.06 yuan from 1.48 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.04 yuan.
Revenue grew 57% to 5.54 billion yuan from 3.52 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 5.26 billion yuan.
The company declared a final dividend of 0.6021 yuan per share and a special dividend of 0.5921 yuan per share, both payable Aug. 29 to shareholders on record as of June 24.
Shares rose 1% during Thursday's trading.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。